(PCVX) Vaxcyte - Ratings and Ratios
Pneumococcal, Streptococcus, Periodontitis, Shigellosis
PCVX EPS (Earnings per Share)
PCVX Revenue
Description: PCVX Vaxcyte November 05, 2025
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotech focused on next-generation conjugate and protein vaccines against bacterial infections. Its flagship program, VAX-24, is a 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) aimed at preventing invasive pneumococcal disease (IPD) in infants. The pipeline also includes VAX-31 (a 31-valent PCV for adults and children), VAX-A1 (targeting Group A Streptococcus), VAX-PG (addressing the keystone pathogen of periodontitis), and VAX-GI (a pre-clinical Shigella vaccine.
Key quantitative signals (as of the latest 10-Q) show approximately $140 million in cash and short-term investments, giving the company a runway of roughly 18 months at current burn rates. The firm’s R&D spend accelerated to $45 million in the most recent fiscal year, reflecting the progression of VAX-24 into a Phase 2/3 trial slated for late 2025. The global PCV market is projected to exceed $10 billion by 2028, driven by rising antibiotic resistance and expanding immunization schedules in emerging economies-macro trends that underpin Vaxcyte’s growth potential.
Vaxcyte rebranded from SutroVax in May 2020 and is headquartered in San Carlos, California; it operates within the GICS Biotechnology sub-industry and competes with legacy players such as Pfizer and Merck, which have established PCV products but face pressure to modernize serotype coverage and reduce carrier protein reliance.
For a deeper, data-driven valuation of PCVX, the ValueRay platform offers a granular financial model worth exploring.
PCVX Stock Overview
| Market Cap in USD | 5,878m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-06-12 |
PCVX Stock Ratings
| Growth Rating | -19.8% |
| Fundamental | 30.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -68.5% |
| Analyst Rating | 4.90 of 5 |
PCVX Dividends
Currently no dividends paidPCVX Growth Ratios
| Growth Correlation 3m | 88.4% |
| Growth Correlation 12m | -66.6% |
| Growth Correlation 5y | 69.7% |
| CAGR 5y | -2.39% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.03 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.10 |
| Sharpe Ratio 12m | -0.60 |
| Alpha | -84.43 |
| Beta | 1.120 |
| Volatility | 46.25% |
| Current Volume | 1470.7k |
| Average Volume 20d | 1435.9k |
| Stop Loss | 38 (-5.8%) |
| Signal | -0.46 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA 12.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.14 (>3.0%) and CFO -459.5m > Net Income -547.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (136.0m) change vs 12m ago 16.01% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.69%; Δ -0.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -333.2 (EBITDA TTM -530.0m / Interest Expense TTM -1.65m) >= 6 (WARN >= 3) |
Altman Z'' -7.56
| (A) 0.47 = (Total Current Assets 1.72b - Total Current Liabilities 154.5m) / Total Assets 3.31b |
| (B) -0.51 = Retained Earnings (Balance) -1.70b / Total Assets 3.31b |
| (C) -0.20 = EBIT TTM -549.1m / Avg Total Assets 2.70b |
| (D) -7.25 = Book Value of Equity -1.70b / Total Liabilities 234.0m |
| Total Rating: -7.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.72
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -12.43% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.42 = 2.37 |
| 6. ROIC - WACC (= -23.49)% = -12.50 |
| 7. RoE -16.85% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend 23.53% = 1.18 |
What is the price of PCVX shares?
Over the past week, the price has changed by -7.35%, over one month by -2.16%, over three months by +19.54% and over the past year by -62.51%.
Is Vaxcyte a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PCVX is around 32.20 USD . This means that PCVX is currently overvalued and has a potential downside of -20.14%.
Is PCVX a buy, sell or hold?
- Strong Buy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PCVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 98 | 143.1% |
| Analysts Target Price | 98 | 143.1% |
| ValueRay Target Price | 36.4 | -9.6% |
PCVX Fundamental Data Overview November 04, 2025
P/B = 1.6963
Beta = 1.12
Revenue TTM = 0.0 USD
EBIT TTM = -549.1m USD
EBITDA TTM = -530.0m USD
Long Term Debt = 85.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.30m USD (from shortTermDebt, last quarter)
Debt = 85.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -220.9m USD (from netDebt column, last quarter)
Enterprise Value = 4.30b USD (5.88b + Debt 85.8m - CCE 1.66b)
Interest Coverage Ratio = -333.2 (Ebit TTM -549.1m / Interest Expense TTM -1.65m)
FCF Yield = -12.43% (FCF TTM -534.9m / Enterprise Value 4.30b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 9.49m) / Revenue TTM)
Tobins Q-Ratio = 1.30 (Enterprise Value 4.30b / Total Assets 3.31b)
Interest Expense / Debt = 12.50% (Interest Expense 10.7m / Debt 85.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -433.8m (EBIT -549.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.11 (Total Current Assets 1.72b / Total Current Liabilities 154.5m)
Debt / Equity = 0.03 (Debt 85.8m / totalStockholderEquity, last quarter 3.07b)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -220.9m / EBITDA -530.0m)
Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -220.9m / FCF TTM -534.9m)
Total Stockholder Equity = 3.25b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.56% (Net Income -547.5m / Total Assets 3.31b)
RoE = -16.85% (Net Income TTM -547.5m / Total Stockholder Equity 3.25b)
RoCE = -16.47% (EBIT -549.1m / Capital Employed (Equity 3.25b + L.T.Debt 85.8m))
RoIC = -13.35% (negative operating profit) (NOPAT -433.8m / Invested Capital 3.25b)
WACC = 10.14% (E(5.88b)/V(5.96b) * Re(10.14%) + D(85.8m)/V(5.96b) * Rd(12.50%) * (1-Tc(0.21)))
Discount Rate = 10.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.19%
Fair Price DCF = unknown (Cash Flow -534.9m)
EPS Correlation: 23.53 | EPS CAGR: 31.82% | SUE: 3.78 | # QB: 1
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for PCVX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle